Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: The Crazy Back-Story To Sarepta Therapeutics' Game-Changing Approval
Sep 21, 2016 (20:12)
Hit or miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.